139 related articles for article (PubMed ID: 35156617)
1. Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients.
Karadeniz H; Cindil E; Babaoğlu H; Avanoğlu Güler A; Bilici Salman R; Satış H; Ataş N; Göker B; Haznedaroğlu Ş; Öztürk MA; Tufan A
Eur J Rheumatol; 2022 Apr; 9(2):75-81. PubMed ID: 35156617
[TBL] [Abstract][Full Text] [Related]
2. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
4. Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea.
Ha SY; Shim YB; Lee MY; Koo BS; Kim JH; Jeon JY; Yoo HJ; Kim YJ; Shin JY; Park MH
Rheumatol Ther; 2021 Mar; 8(1):395-409. PubMed ID: 33496958
[TBL] [Abstract][Full Text] [Related]
5. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
[TBL] [Abstract][Full Text] [Related]
6. Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs.
Ozen G; Pedro S; England BR; Mehta B; Wolfe F; Michaud K
ACR Open Rheumatol; 2019 Sep; 1(7):424-432. PubMed ID: 31777822
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study.
Paroli M; Becciolini A; Bravi E; Andracco R; Nucera V; Parisi S; Ometto F; Lumetti F; Farina A; Del Medico P; Colina M; Lo Gullo A; Ravagnani V; Scolieri P; Larosa M; Priora M; Visalli E; Addimanda O; Vitetta R; Volpe A; Bezzi A; Girelli F; Molica Colella AB; Caccavale R; Di Donato E; Adorni G; Santilli D; Lucchini G; Arrigoni E; Platè I; Mansueto N; Ianniello A; Fusaro E; Ditto MC; Bruzzese V; Camellino D; Bianchi G; Serale F; Foti R; Amato G; De Lucia F; Dal Bosco Y; Foti R; Reta M; Fiorenza A; Rovera G; Marchetta A; Focherini MC; Mascella F; Bernardi S; Sandri G; Giuggioli D; Salvarani C; Franchina V; Molica Colella F; Ferrero G; Ariani A
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629770
[No Abstract] [Full Text] [Related]
8. Real-life experience of tofacitinib in patients with treatment-resistant rheumatoid arthritis: A 5-year follow-up: Monocentric experience.
Pehlivan O
North Clin Istanb; 2022; 9(4):376-384. PubMed ID: 36276563
[TBL] [Abstract][Full Text] [Related]
9. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope J; Takeuchi T; Hyrich K; Winthrop KL; Aletaha D; Stamm T; Schoones JW; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):107-118. PubMed ID: 36376026
[TBL] [Abstract][Full Text] [Related]
10. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China.
Shi Y; Xie Y; Zhang G; Feng Y
Intern Emerg Med; 2022 Apr; 17(3):703-714. PubMed ID: 34559374
[TBL] [Abstract][Full Text] [Related]
12. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting.
Choi S; Ghang B; Jeong S; Choi D; Lee JS; Park SM; Lee EY
Semin Arthritis Rheum; 2021 Aug; 51(4):685-691. PubMed ID: 34139521
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment.
Drosos AA; Pelechas E; Kaltsonoudis E; Voulgari PV
Curr Rheumatol Rep; 2020 Jun; 22(8):44. PubMed ID: 32591916
[TBL] [Abstract][Full Text] [Related]
14. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
15. Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy.
Conigliaro P; D'Antonio A; D'Erme L; Lavinia Fonti G; Triggianese P; Bergamini A; Chimenti MS
PLoS One; 2023; 18(2):e0281213. PubMed ID: 36730337
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
17. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindström U; Turesson C; Frisell T
Rheumatology (Oxford); 2022 Oct; 61(10):3952-3962. PubMed ID: 35134119
[TBL] [Abstract][Full Text] [Related]
19. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center.
Kaltsonoudis E; Pelechas E; Voulgari PV; Drosos AA
Semin Arthritis Rheum; 2019 Feb; 48(4):597-602. PubMed ID: 30075990
[TBL] [Abstract][Full Text] [Related]
20. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]